Source: Eur Respir J 2003; 22: 251-257
Disease area: Sleep and breathing disorders



Rating:

Share or cite this content

Citations should be made in the following way:
Harsch I.A., Konturek P.C., Koebnick C., Kuehnlein P.P., Fuchs F.S., Pour Schahin S., Wiest G.H., Hahn E.G., Lohmann T., Ficker J.H.. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J 2003; 22: 251-257

Member's Comments

No comment yet.

Related content which might interest you: Metabolic disturbances in patients with obstructive sleep apnoea syndrome Source: Eur Respir Rev 2007; 16: 196-202 Year: 2007 Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 332s Year: 2004 Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP Source: Eur Respir J 2007; 30: 496-500 Year: 2007 Effect of continuous positive airway pressure treatment on hypoadiponectinemia in male patients with obstructive sleep apnea syndrome Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005 Effect of 8 week CPAP therapy on insulin resistance, serum leptin and lipid concentrations among obstructive sleep apnea hypopnea syndrome (OSAS) patients Source: Eur Respir J 2004; 24: Suppl. 48, 330s Year: 2004 Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients Source: Eur Respir J 2009; 34: 694 Year: 2009 Impact of obstructive sleep apnoea (OSA) on glucose metabolism Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment Year: 2007 The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome Source: Eur Respir J 2004; 24: Suppl. 48, 113s Year: 2004 The effect of theophylline and CPAP on cytokine release in patients with obstructive sleep apnea syndrome (OSAS) Source: Eur Respir J 2006; 28: Suppl. 50, 216s Year: 2006 Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients Source: Eur Respir J 2001; 18: Suppl. 33, 334s Year: 2001 The influence of 3-weeks‘ therapy of continous positive airway pressure (CPAP) on serum leptin and homocysteine concentration in patients with obstructive sleep apnea (OSA) Source: Annual Congress 2005 - Metabolic control in OSA Year: 2005 Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS) Source: Annual Congress 2004 - Systemic and metabolic effects from OSA Year: 2004 Elevated leptin is associated with impaired glucose tolerance in obstructive sleep apnoea (OSA) Source: Eur Respir J 2006; 28: Suppl. 50, 573s Year: 2006 Influence of treatment on leptin levels in patients with obstructive sleep apnoea Source: Eur Respir J 2004; 23: 601-604 Year: 2004 Should obstructive sleep apnoea be treated regarding the related cardiovascular risk in non sleepy patients? Source: Annual Congress 2006 - Obstructive sleep apnoea and cardiovascular diseases Year: 2006 Serum leptin levels in obstructive sleep apnoea patients Source: Annual Congress 2007 - Metabolic consequences of obstructive sleep apnoea Year: 2007 CPAP decreases plasma levels of soluble tumour necrosis factor-α receptor 1 in obstructive sleep apnoea Source: Eur Respir J 2008; 32: 1009-1015 Year: 2008 Effect of continuous positive airway pressure therapy on metabolic control in patients with morbid obesity and obstructive sleep apnoea Source: Annual Congress 2013 –Burn after reading: inflammation in sleep disordered breathing Year: 2013 Cardiovascular and metabolic effects of CPAP in obese males with OSA Source: Eur Respir J 2007; 29: 720-727 Year: 2007 Effects of CPAP treatment on physical fitness in patients with obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 97s Year: 2003